HALF LIFE DETERMINATION OF COVID-19 ANTIBODIES AMONG VACCINATED AND NON-VACCINATED PEOPLE
Main Article Content
Keywords
Covid-19, Antibodies, RT-PCR, SARS-CoV-2, ELISA
Abstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had a profound impact on global health, economy, and society. Serological investigations, play a pivotal role in understanding the immune response generated in these individuals, including the production of specific antibodies. This retrospective cross-sectional study was conducted in Faisalabad, Pakistan, aimed to investigate the prevalence of COVID-19 and the dynamics of SARS-CoV-2 antibodies among vaccinated and non-vaccinated people. A total of 300 participants from three different medical institutes were enrolled among three different medical institutes and the participants were divided into two groups based on their vaccination status: non-vaccinated (n=150) and vaccinated (n=150).ELISA and PCR were performed on blood tests for the detection of antibodies and reactive cases. Based on gender howed that in the non-vaccinated group, 85 individuals (56.6%) were males, while 65 individuals (43.3%) were females. In the vaccinated group, there were 80 males (53.3%) and 70 females (46.6%). Regarding age groups, the participants were categorized into four groups. In the non-vaccinated group, 50 individuals (33.3%) were in the age range of 21-30 years, as were 50 individuals (33.3%) in the vaccinated group. The 31-40 year age group had 30 participants (20.0%) in both the non-vaccinated and vaccinated groups. In the non-vaccinated group, 30 individuals (20.0%) were in the 41-50 year age range, while 40 individuals (26.6%) fell in the same age group in the vaccinated group. For individuals above 50 years of age, there were 40 participants (26.6%) in the non-vaccinated group and 30 participants (20.0%) in the vaccinated group. At the end of the study, 22 of the participants were non-reactive against SARS-Cov-2 IgG antibodies out of 150 that were non-vaccinated while total 29 individuals were non-reactive against IgG antibodies that were vaccinated. This study emphasizes the urgent need for enhanced genomic surveillance in Pakistan to monitor the emergence and spread of SARS-CoV-2 variants, highlighting the importance of timely detection, and understanding their implications for public health interventions and vaccine development.
References
2. BADULAK, J., ANTONINI, M. V., STEAD, C. M., SHEKERDEMIAN, L., RAMAN, L., PADEN, M. L., AGERSTRAND, C., BARTLETT, R. H., BARRETT, N. & COMBES, A. 2021. Extracorporeal membrane oxygenation for COVID-19: updated 2021 guidelines from the extracorporeal life support organization. Asaio Journal, 67, 485.
3. BIKDELI, B., TALASAZ, A. H., RASHIDI, F., BAKHSHANDEH, H., RAFIEE, F., REZAEIFAR, P., BAGHIZADEH, E., MATIN, S., JAMALKHANI, S. & TAHAMTAN, O. 2022. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. Thrombosis and haemostasis, 122, 131-141.
4. BÖGER, B., FACHI, M. M., VILHENA, R. O., COBRE, A. F., TONIN, F. S. & PONTAROLO, R. 2021. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. American journal of infection control, 49, 21-29.
5. BWIRE, G. M. & PAULO, L. S. 2020. Coronavirus disease-2019: is fever an adequate screening for the returning travelers? Tropical medicine and health, 48, 1-3.
6. CAO, Y., WANG, J., JIAN, F., XIAO, T., SONG, W., YISIMAYI, A., HUANG, W., LI, Q., WANG, P. & AN, R. 2022. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature, 602, 657-663.
7. CHAN, L., CHAUDHARY, K., SAHA, A., CHAUHAN, K., VAID, A., ZHAO, S., PARANJPE, I., SOMANI, S., RICHTER, F. & MIOTTO, R. 2021. AKI in hospitalized patients with COVID-19. Journal of the American Society of Nephrology: JASN, 32, 151.
8. CHOW, E. J., UYEKI, T. M. & CHU, H. Y. 2023. The effects of the COVID-19 pandemic on community respiratory virus activity. Nature Reviews Microbiology, 21, 195-210.
9. CUCINOTTA, D. & VANELLI, M. 2020. WHO declares COVID-19 a pandemic. Acta bio medica: Atenei parmensis, 91, 157.
10. GAZIT, S., SHLEZINGER, R., PEREZ, G., LOTAN, R., PERETZ, A., BEN-TOV, A., HERZEL, E., ALAPI, H., COHEN, D. & MUHSEN, K. 2022. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naturally acquired immunity versus vaccine-induced immunity, reinfections versus breakthrough infections: a retrospective cohort study. Clinical Infectious Diseases, 75, e545-e551.
11. GOYAL, P., CHOI, J. J., PINHEIRO, L. C., SCHENCK, E. J., CHEN, R., JABRI, A., SATLIN, M. J., CAMPION JR, T. R., NAHID, M. & RINGEL, J. B. 2020. Clinical characteristics of Covid-19 in New York city. New England Journal of Medicine, 382, 2372-2374.
12. GRIFONI, A., WEISKOPF, D., RAMIREZ, S. I., MATEUS, J., DAN, J. M., MODERBACHER, C. R., RAWLINGS, S. A., SUTHERLAND, A., PREMKUMAR, L. & JADI, R. S. 2020. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell, 181, 1489-1501. e15.
13. GUAN, W.-J., WEI, C.-H., CHEN, A.-L., SUN, X.-C., GUO, G.-Y., ZOU, X., SHI, J.-D., LAI, P.-Z., ZHENG, Z.-G. & ZHONG, N.-S. 2020. Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial. Journal of Thoracic Disease, 12, 3448.
14. HALL, V. J., FOULKES, S., CHARLETT, A., ATTI, A., MONK, E. J., SIMMONS, R., WELLINGTON, E., COLE, M. J., SAEI, A. & OGUTI, B. 2021. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet, 397, 1459-1469.
15. HARTNACK, S., EUSEBI, P. & KOSTOULAS, P. 2021. Bayesian latent class models to estimate diagnostic test accuracies of COVID‐19 tests. Journal of medical virology, 93, 639-640.
16. HERNÁNDEZ‐HUERTA, M. T., MAYORAL, L. P. C., NAVARRO, L. M. S., MAYORAL‐ANDRADE, G., MAYORAL, E. P. C., ZENTENO, E. & PÉREZ‐CAMPOS, E. 2021. Should RT‐PCR be considered a gold standard in the diagnosis of COVID‐19? Journal of medical virology, 93, 137.
17. HUANG, C., WANG, Y., LI, X., REN, L., ZHAO, J., HU, Y., ZHANG, L., FAN, G., XU, J. & GU, X. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395, 497-506.
18. IBARRONDO, F. J., HOFMANN, C., FULCHER, J. A., GOODMAN-MEZA, D., MU, W., HAUSNER, M. A., ALI, A., BALAMURUGAN, A., TAUS, E. & ELLIOTT, J. 2021. Primary, recall, and decay kinetics of SARS-CoV-2 vaccine antibody responses. ACS nano, 15, 11180-11191.
19. KHOSHKAM, Z., AFTABI, Y., STENVINKEL, P., LAWRENCE, B. P., REZAEI, M. H., ICHIHARA, G. & FEREIDOUNI, S. 2021. Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. Journal of Advanced Research, 31, 49-60.
20. LUMLEY, S. F., O’DONNELL, D., STOESSER, N. E., MATTHEWS, P. C., HOWARTH, A., HATCH, S. B., MARSDEN, B. D., COX, S., JAMES, T. & WARREN, F. 2021. Antibody status and incidence of SARS-CoV-2 infection in health care workers. New England Journal of Medicine, 384, 533-540.
21. MATHUR, R., RENTSCH, C. T., MORTON, C. E., HULME, W. J., SCHULTZE, A., MACKENNA, B., EGGO, R. M., BHASKARAN, K., WONG, A. Y. & WILLIAMSON, E. J. 2021. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. The Lancet, 397, 1711-1724.
22. MOHAN, B. & NAMBIAR, V. 2020. COVID-19: an insight into SARS-CoV-2 pandemic originated at Wuhan City in Hubei Province of China. J Infect Dis Epidemiol, 6, 146.
23. NG, O. T., MARIMUTHU, K., KOH, V., PANG, J., LINN, K. Z., SUN, J., DE WANG, L., CHIA, W. N., TIU, C. & CHAN, M. 2021. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. The Lancet infectious diseases, 21, 333-343.
24. POOLEY, N., ABDOOL KARIM, S. S., COMBADIÈRE, B., OOI, E. E., HARRIS, R. C., EL GUERCHE SEBLAIN, C., KISOMI, M. & SHAIKH, N. 2023. Durability of vaccine-induced and natural immunity against COVID-19: a narrative review. Infectious Diseases and Therapy, 12, 367-387.
25. SHANMUGARAJ, B., SIRIWATTANANON, K., WANGKANONT, K. & PHOOLCHAROEN, W. 2020. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pacific journal of allergy and immunology, 38, 10-18.
26. SHEIKH, A., MCMENAMIN, J., TAYLOR, B. & ROBERTSON, C. 2021. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. The Lancet, 397, 2461-2462.
27. SIDIQ, Z., HANIF, M., DWIVEDI, K. K. & CHOPRA, K. 2020. Benefits and limitations of serological assays in COVID-19 infection. indian journal of tuberculosis, 67, S163-S166.
28. TAKAHASHI, T., ELLINGSON, M. K., WONG, P., ISRAELOW, B., LUCAS, C., KLEIN, J., SILVA, J., MAO, T., OH, J. E. & TOKUYAMA, M. 2020. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature, 588, 315-320.
29. TRETYN, A., SZCZEPANEK, J., SKORUPA, M., JARKIEWICZ-TRETYN, J., SANDOMIERZ , D., DEJEWSKA, J., CIECHANOWSKA, K., JARKIEWICZ-TRETYN, A., KOPER , W. & PAŁGAN, K. 2021. Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccination. Cells, 10, 1952.
30. WANG, D., HU, B., HU, C., ZHU, F., LIU, X., ZHANG, J., WANG, B., XIANG, H., CHENG, Z. & XIONG, Y. 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. jama, 323, 1061-1069.
31. WU, C.-T., LIDSKY, P. V., XIAO, Y., LEE, I. T., CHENG, R., NAKAYAMA, T., JIANG, S., DEMETER, J., BEVACQUA, R. J. & CHANG, C. A. 2021. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell metabolism, 33, 1565-1576. e5.
32. YAN, L., ZHANG, H.-T., GONCALVES, J., XIAO, Y., WANG, M., GUO, Y., SUN, C., TANG, X., JING, L. & ZHANG, M. 2020. An interpretable mortality prediction model for COVID-19 patients. Nature machine intelligence, 2, 283-288.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Muhammad Mudassar
Institute of Microbiology, Faculty of Life Sciences, Government College University, Faisalabad 38000, Pakistan.
Muhammad Shafique
Institute of Microbiology, Faculty of Life Sciences, Government College University, Faisalabad 38000, Pakistan.
Muhammad Hidayat Rasool
Institute of Microbiology, Faculty of Life Sciences, Government College University, Faisalabad 38000, Pakistan.
Bilal Aslam
Institute of Microbiology, Faculty of Life Sciences, Government College University, Faisalabad 38000, Pakistan.
Farwa Batool Shamsi
Department of Pathology, Faisalabad Medical University Faisalabad 38000, Pakistan.